Celera Genomics Group's deal to access functional genomics technology from Isis Pharmaceuticals Inc. may seem paradoxical, as it allows ISIP and not CRA to commercialize resulting gene function information in a database. But as a piece of CRA's move downstream from DNA sequencing, the deal implies that CRA has indeed decided its future lies somewhere outside database subscriptions.

Peter Barrett, CRA's chief business officer, said ISIP's GeneTrove